Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022

Trends and Short-term Outcomes of Surgically Resected Early-onset Colorectal Cancer in Switzerland Between 2003 and 2022: A Retrospective National Registry Study

Registry ID

NCT07763314

Source registry

NCT

Status

COMPLETED

Study type

OBSERVATIONAL

Sponsor

Cantonal Hospital of St. Gallen

Enrollment

73771

Start date

2003-01-01

Completion date

2023-03-01

Last update

2026-08-13

Conditions

• Early Onset Colorectal Cancer
• Colorectal Cancer (CRC)

Summary

The incidence of early-onset colorectal cancer (EOCRC; patients younger than 50 years) has increased worldwide over recent decades. This study aimed to provide nationwide evidence on surgically treated EOCRC in Switzerland.

Interventions

• PROCEDURE: Early-onset colorectal cancer resection
• PROCEDURE: Late-onset colorectal cancer resection

Inclusion criteria

Inclusion Criteria: \- All patients with colorectal cancer resection in Switzerland between 2003 and 2022.

Exclusion criteria

Exclusion Criteria: * incomplete case documentation * age under 15 years * other hospitals than general or surgical hospitals * no index operation

Primary outcomes

[{"measure":"Incidence","timeFrame":"2003 - 2022"}]

Locations

• HOCH Health Ostschweiz, Kantonsspital St.Gallen, Sankt Gallen, Switzerland

Related clinical trials

• Transcutaneous Electrical Acustimulation on Postoperative Bowel Function Recovery in Elderly Patients
• A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
• Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
• Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

View on source registry